TCM
BLUE

Tekla Capital Management’s bluebird bio BLUE Stock Holding History

Tekla Capital Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-5,203
Closed -$5.77M – 137
2015
Q3 		$5.77M Buy
+5,203
New +$9.49M 0.21% 95
2014
Q4 		– Sell
-9,140
Closed -$4.25M – 100
2014
Q3 		$4.25M Buy
+9,140
New +$4.22M 0.2% 87

Other funds holding BLUE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Tekla Capital Management's BLUE Position: Q4 2020 in Review

Tekla Capital Management sold out of bluebird bio (BLUE) in Q4 2020, closing a stake of 6,500 shares — an estimated $4.54M sold.

Tekla Capital Management first reported a position in BLUE in Q1 2014 and held it in 27 quarters. The position peaked at $14.3M in Q1 2019. 262 funds tracked by Wall St. Rank hold BLUE as of Q4 2020.

  • Tekla Capital Management reported no remaining bluebird bio position as of Q4 2020 after selling out during the quarter.
  • Tekla Capital Management sold 6,500 bluebird bio shares in Q4 2020, an estimated $4.54M.
  • Tekla Capital Management first reported a position in bluebird bio in Q1 2014 and held it in 27 quarters.
  • Tekla Capital Management's bluebird bio position peaked at $14.3M in Q1 2019.
  • 262 funds tracked by Wall St. Rank held bluebird bio as of Q4 2020.

Based on Tekla Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.